Valutazione del turn over dei farmaci antiretrovirali in particolare da IP a NNRTI

Valutazione del turn over dei farmaci antiretrovirali in particolare da IP a NNRTI

Authors

  • Sergio Sabbatani Unità Operativa di Malattie Infettive Policlinico S. Orsola-Malpighi – Bologna

  • Raffaella Cesari Farmacia Ospedale Maggiore – Bologna

  • Emanuela Pipitone Osservatorio Epidemiologico Bolognese

  • Francesco Chiodo Unità Operativa di Malattie Infettive Policlinico S. Orsola-Malpighi – Bologna



DOI:

https://doi.org/10.7175/fe.v4i1.759

Abstract

Objective: To determine the turnover for each antiretroviral drugs present in TP’s of patients under care for HIV infection, with a special focus on PI’s and NNRTI’s. Design/Methods: We have carried out a retrospective analysis with the aim of evaluating the turnover of each drug in the 3-year period 1998-2000. Using a specifically designed software, it was possible to determine the changes in TP for each single patient. We then calculated a different weighted percentage for each drug on the basis of the time interval from the drug entry to its exclusion from the TP: the shorter the interval, the greater the assigned weight. Finally we carried out a cluster analysis in order to obtain homogeneous groups of molecules showing the same degree of therapy switches. We established that a higher average score corresponds to a higher therapy switch rate. Results: Zidovudine/Lamivudine combination, Indinavir, Lamivudine, Nerivapine and Nelfinavir are the drugs with the lowest turnover. On the other hand, Saquinavir, Didanosine, Zidavudine, and Stavudine show the highest turnover. Conclusion: The introduction of NNRTI’s with the associated switch from PI’s (Saquinavir, Nelfinavir) and the Zidavudine/Lamivudine combination enables a simplification of the treatment. This practice appeared to be a good choice in the 3-year period under consideration. The adoption of these therapeutic solutions reduce the turnover, consequently giving more stability to TP’s.

Downloads

Published

2003-03-15

How to Cite

Sabbatani, S., Cesari, R., Pipitone, E., & Chiodo, F. (2003). Valutazione del turn over dei farmaci antiretrovirali in particolare da IP a NNRTI. Farmeconomia. Health Economics and Therapeutic Pathways, 4(1), 5–10. https://doi.org/10.7175/fe.v4i1.759

Issue

Vol. 4 No. 1 (2003)

Section

Brief drug profile

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)